Triumeq is a fixed-dose combination formulation composed of three anti-HIV drugs—abacavir, dolutegravir, and lamivudine—and is indicated for the treatment of HIV-1 infection in specific populations. As an optimized combination of an integrase strand transfer inhibitor and nucleoside reverse transcriptase inhibitors, this medication enhances medication convenience, while its specification characteristics and storage requirements must also be strictly followed.
What Are the Indications for Triumeq?
Core Therapeutic Positioning
Triumeq is explicitly indicated for the treatment of HIV-1 infection in adults and pediatric patients aged 3 months and older with a body weight of at least 6 kilograms.
The drug exerts a synergistic effect through a triple mechanism of action: dolutegravir, as an integrase inhibitor, blocks viral DNA integration. Abacavir and lamivudine, as nucleoside reverse transcriptase inhibitors, competitively inhibit viral replication by forming active metabolites.
Important Usage Restrictions
This product is not recommended for patients with existing integrase resistance-associated substitutions or those with clinically suspected INSTI resistance, as the dosage of dolutegravir is insufficient in such cases.
For HIV-1/HBV coinfected patients with lamivudine-resistant HBV variants, additional treatment regimens or alternative options should be considered.
Dosage Form, Specifications and Properties of Triumeq
Formulation and Specification Parameters
Each tablet contains 600 mg of abacavir (equivalent to 702 mg as abacavir sulfate), 50 mg of dolutegravir (equivalent to 52.6 mg as dolutegravir sodium), and 300 mg of lamivudine.
The tablet is purple, biconvex, and oval-shaped, with the marking "572Tri" embossed on one side.
Physicochemical Property Description
The tablet’s film coating contains ingredients such as black iron oxide, red iron oxide, polyethylene glycol, partially hydrolyzed polyvinyl alcohol, talc, and titanium dioxide.
The tablet core contains excipients including D-mannitol, magnesium stearate, microcrystalline cellulose, povidone, and sodium starch glycolate.
Storage Methods for Triumeq
Storage Environment Requirements
This product must be stored at room temperature between 20°C and 25°C (68°F and 77°F), with short-term exposure to the range of 15°C to 30°C (59°F to 86°F) permitted.
Packaging and Stability
The tablets are packaged in brown bottles containing a desiccant, with 30 tablets per bottle (NDC 49702-231-13), and the original packaging must be kept intact at all times.
During storage, strict protection against moisture is required: ensure the bottle cap is always tightly closed, and the built-in desiccant must not be removed.
